Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Nichi-Iko Launches Another Recall, Now Pulling 8 More APIs/9 Products
Nichi-Iko Pharmaceutical said on May 18 that it has started voluntary recalls for eight APIs/nine products due to compliance and quality issues after pulling as many as 12 APIs/15 products from shelves last month, which has triggered shipment curbs for…
To read the full story
Related Article
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
- Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- Administrative Penalty on Nichi-Iko Possible by March-End over Recalls
January 15, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
- Nichi-Iko Recalls 4 More Products Including Theophylline due to Deviations from Approved Specifications
December 11, 2020
- Some Hospitals Shun New Nichi-Iko Generics after Massive Recalls, President Reveals
November 13, 2020
- Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- Towa Voluntarily Recalls Pentasa Generics due to Inadequate Shipment Testing at Contract Manufacturer Nichi-Iko
May 28, 2020
- Nichi-Iko Recall Hits Towa’s Teprenone Supply
April 23, 2020
- Sawai Curbing Shipments for 2 More Drugs after Nichi-Iko’s Massive Recalls
April 21, 2020
- Nichi-Iko Recalling 12 APIs/15 Products over Quality, Compliance Issues
April 9, 2020
BUSINESS
- Regeneron Files MM Drug Linvoseltamab in Japan
November 6, 2026
- Fuji Pharma Recalls Eylea Biosimilar Lots over Faulty Finger Grips
November 6, 2026
- Medipal Sets Dec. 15 Shareholder Meeting, Opposes Chairman’s Ouster
November 6, 2026
- Nitrosamine Impurities Reported for Generic Telmisartan; No Recalls Planned
November 6, 2026
- Bracco Japan to Acquire Iopamiron from Bayer in July 2027
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…